Home / Stock ratings / TEVA
Stock rating · Pharmaceutical Preparations
Teva Pharmaceutical Industries Limited (TEVA) Stock Rating & Analysis
As of October 9, 2026, MELANY rates Teva Pharmaceutical Industries Limited 62 out of 100 (Hold). Its highest factor score is catalyst setup at 85, and its lowest is business quality at 37.
MELANY ratingRated 2026-10-09TEVA · composite score
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. It derives half of its sales from North America and accounts for a high-single-digit percentage of total US generic prescriptions, with a significant presence in Europe, Japan, Russia, and Israel. Beyond generics, it has a portfolio of innovative medicines and biosimilars in two main therapeutic areas, neurology and immunology.
Rating as of 2026-10-09 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why TEVA scores 62/100
TEVA's 8 factor scores run from 37 to 85, and 4 of them sit above its composite of 62. Here is how TEVA breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 13.7x, earnings growth accelerating
- PEG ratio 0.71 (< 1 = undervalued)
Margins, returns on capital, and balance-sheet strength.
- Gross margin 52%
Direction and relative strength of the recent share-price trend.
- Price +9.3% above 50-day MA
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 3 of last 4 quarters
- Earnings in 25 days (strong beat history)
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
- Earnings in 25 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How TEVA compares
As of October 14, 2026, Teva Pharmaceutical Industries Limited is tied for 12th of the 15 companies with a MELANY rating page in its SEC industry group (Pharmaceutical Preparations), where the average score is 69.
Key risks for TEVA
- High debt-to-equity ratio 2.2x, rate-sensitive balance sheet
- Trading near 52-week high, limited upside without new positive catalyst
Sector and theme context
Teva Pharmaceutical Industries Limited sits in the Healthcare sector theme, which MELANY currently rates 59/100 for strength. Theme strength feeds TEVA's momentum and catalyst factors above.
Tracking TEVA
Teva Pharmaceutical Industries Limited rates Hold right now, so MELANY is not flagging a fresh entry. Add TEVA to a watchlist in the app to follow its rating; an alert the moment it changes is part of Pro, free for 30 days.
How MELANY rates TEVA
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Teva Pharmaceutical Industries Limited's 62/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about TEVA
Is Teva Pharmaceutical Industries Limited (TEVA) a buy?
As of 2026-10-09, MELANY rated Teva Pharmaceutical Industries Limited Hold with a composite score of 62/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Teva Pharmaceutical Industries Limited's MELANY score?
Teva Pharmaceutical Industries Limited (TEVA) has a MELANY composite score of 62/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the TEVA stock rating calculated?
MELANY scores TEVA from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Teva Pharmaceutical Industries Limited stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Teva Pharmaceutical Industries Limited (TEVA) Hold with a composite of 62/100 as of 2026-10-09. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the TEVA stock price forecast?
MELANY does not publish price targets or forecasts for TEVA. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 62/100 across eight factors for Teva Pharmaceutical Industries Limited, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is TEVA stock overvalued or undervalued?
MELANY's valuation factor currently reads 56/100 for Teva Pharmaceutical Industries Limited, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives TEVA's read.
What price should I buy TEVA at?
MELANY is not flagging a fresh entry for TEVA at its current Hold rating, so there is no entry zone to publish right now. Add TEVA to a watchlist in the app to follow it; an alert the moment the rating changes is part of Pro, free for 30 days.
What are the risks of buying TEVA stock?
The top risks MELANY currently flags for Teva Pharmaceutical Industries Limited: High debt-to-equity ratio 2.2x, rate-sensitive balance sheet; Trading near 52-week high, limited upside without new positive catalyst. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Teva Pharmaceutical Industries Limited a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 37/100 for Teva Pharmaceutical Industries Limited, and earnings track record, at 58/100. The 62/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will TEVA stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 79/100 for TEVA right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this TEVA rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-09. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores TEVA continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, TEVA included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.